Table 1 Parameter estimates related to efficacy of low-dose computed tomography screening
Table 2 Calibration parameters to adjust baseline survival of screen-detected non-small-cell cancers to match stage-specific survival curves and reported mortality reductions in National Lung Screening Trial (NLST)
Table 3 Incremental lung cancer-specific survival between low-dose computed tomography screening and control arm, by stage and years survived from diagnosis of non-small-cell lung cancer, Cancer Risk Management Model-Lung Cancer (CRMM-LC) and National Lung Screening Trial (NLST)
Table 4 Cumulative number of lung cancer deaths and percent mortality reduction due to low-dose computed tomography screening, by study year, Cancer Risk Management Model-Lung Cancer (CRMM-LC) screening model and National Lung Screening Trial (NLST)
Table 5 Selected screening program scenarios, Cancer Risk Management Model-Lung Cancer (CRMM-LC) and Cancer Intervention and Surveillance Modeling Network (CISNET)
Figure 1 Number of new lung cancer cases, by screen arm and study year, Cancer Risk Management Model-Lung Cancer (CRMM-LC) screening model and National Lung Screening Trial (NLST)
Figure 2 Cumulative number of new lung cancer cases, by screen arm and study year, Cancer Risk Management Model-Lung Cancer (CRMM-LC) screening model and National Lung Screening Trial (NLST)
